Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

PHASE3TerminatedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

March 31, 2010

Conditions
Diabetes, Type 1
Interventions
DRUG

Technosphere Insulin

Technosphere Insulin Inhalation Powder 15U or 30U

DRUG

Insulin glargine

Lantus-injectible supplied as 3mL (300 units) pens

DRUG

Insulin lispro

Humalog autopen cartridges pre-filled with 3mL (300 units)

Trial Locations (22)

27834

Endocrine Research Physicians East PA, Greenville

28803

Mountain Diabetes & Endocrine Center, Asheville

30309

Atlanta Diabetes Associates, Atlanta

33136

University of Miami Diabetes Research Institute, Miami

University of Miami School of Medicine, Miami

38133

AM Diabetes and Endocrinology Center, Barrtlett

44060

Your Diabetes Endocrine Nutrition Group, Inc., Mentor

59101

Deaconess Billings Clinic Research Center, Billings

63110

Washington University School of Medicine, St Louis

75230

Dallas Diabetes & Endocrine Center, Dallas

75246

Baylor Endocrine Center, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

80045

Barbara Davis Center for Diabetes Young Adult Clinic, Aurora

92037

The Whittier Institute for Diabetes Clinical Trials, La Jolla

92648

Diabetes/Lipid Management and Research Center, Huntington Beach

94401

Dorothy L & James E Frank Diabetes Research Institute, San Mateo

97239

OHSU Diabetes Center Research Oregon Health & Science University, Portland

98105

Diabetes Care Center, Seattle

70112-2699

Tulane University Health Sciences Center, New Orleans

05403

Diabetes Research Center -Fletcher Allen Health Care, South Burlington

-90035-170

Centro de Pesquisas em Diabetes Ltda, Porto Alegre

01244-030

CPClin-Centro de Pesquisas Clinicas, São Paulo

Sponsors
All Listed Sponsors
lead

Mannkind Corporation

INDUSTRY